Infectious Diseases News

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it won the Gold Edison Award 2026 for its AI-powered Viz Hemorrhage solution. This marks the company’s fourth Edison Award and reinforces Viz.ai’s leadership in building the agentic infrastructure that enables artificial intelligence to operate directly within hospitals. Viz.ai was recognized in the Health, Medical & Biotech category for its groundbreaki...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck press release announcing European Commission approval of ENFLONSIA...

ALBANY, N.Y. & SHANGHAI--(BUSINESS WIRE)--Drug Farm today announced that preliminary immunologic and clinical results from its Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, will be presented in a podium session at IMMUNOLOGY2026, taking place April 15–19, 2026, in Boston, Massachusetts. The presentation will highlight early evidence of clinical benefit and pharmacodynamic improvement in patients with ROSAH syndrome, a rare genetic autoinflammatory disease driven by disease-ca...

MUNICH--(BUSINESS WIRE)--At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next‑generation sequencing (NGS) typing. These latest developments underscore Bruker’s continued commitment to advancing integrated, high‑performance solutions that support laboratories in addressing evolving infectious disease challenges. MALDI Biotyper® Workflow and Identification Enhancements To further streamline routine MALDI‑TOF w...

MUNICH--(BUSINESS WIRE)--At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operati...

CANTON, Mass.--(BUSINESS WIRE)--Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first-in-class drug against BK polyomavirus. BK virus infections are a major cause of complications in transplant patients, with no approved treatments. The company is pioneering an oral therapy that addresses the full spectrum of BK infection, from early reactivation thr...

NEW YORK--(BUSINESS WIRE)--Wisp, the largest pure play women’s telehealth company in the U.S., today announced a partnership with Visby Medical, a leader in rapid at-home PCR diagnostics, in recognition of STI Awareness Week. Through the partnership, the two companies will expand access to Visby’s FDA-authorized at-home PCR STI test, with Wisp providing follow-up telehealth care for patients who test positive for chlamydia, gonorrhea, or trichomoniasis. According to the World Health Organizatio...

BOSTON--(BUSINESS WIRE)--Delve Bio announces data showing Delve Detect enables neurologists to treat CNS infections when conventional testing fails at AAN Annual Meeting...

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (TSX: COV; OTCQX: CVALF), an advanced medical technologies company, today announced a series of important milestones reflecting the Company's growing market development and commercial momentum, and deepening engagement across the vascular access, infection prevention, and wound care sectors. Strong Engagement at Infusion Nurses Society Annual Meeting Covalon had a strong presence at the Infusion Nurses Society (INS) Annual Meeting...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Epioxa™ HD / Epioxa™ (“Epioxa”) for the treatment of keratoconus, a rare, sight-threatening disease...